CLAIMS

1. Use of a combination of nerve growth factor (NGF) and sesamin, in the manufacture of a medicament for the treatment of an ocular disorder known to be treatable by NGF, wherein the medicament is to be topically administered.

2. An ophthalmic composition comprising nerve growth factor (NGF), sesamin, and at least one ophthalmically acceptable excipient.

3. A kit comprising:

a) an ophthalmic composition comprising nerve growth factor (NGF), and

b) an ophthalmic composition comprising sesamin.

4. The use according to claim 1, the ophthalmic composition according to claim 2 or the kit according to claim 3, wherein said NGF has the aminoacid sequence of SEQ. ID NO.1 or of SEQ ID NO. 2.

5. The use according to claim 1 or 4, the ophthalmic composition according to claim 2 or 4 or the kit according to claim 3 or 4, wherein said NGF is recombinant human NGF.

6. The use according to any one of claims 1, 4 or 5, the ophthalmic composition according to any one of claims 2, 4 or 5 or the kit according to any one of claims 3, 4 or 5, wherein said NGF has a purity higher than 70%, more preferably higher than 80% w/w, higher than 90% w/w, higher than 95% w/w, higher than 98% w/w or higher than 99% w/w.

7. The use as claimed in any one of claims 1, 4, 5 or 6, the ophthalmic composition according to any one of claims 2, 4, 5 or 6 or the kit according to any one of claims 3, 4, 5 or 6, wherein said sesamin is a purified compound.

8. The use, ophthalmic composition or kit as claimed in claim 7, wherein said sesamin has purity higher than 70% w/w, more preferably higher than 80% w/w, higher than 90% w/w or higher than 95% w/w.

9. The ophthalmic composition according to any one of claims 2, 4, 5, 6, 7 or 8, or the kit according to any one of claim 3, 4, 5, 6, 7 or 8, wherein said compositions comprise one or more excipients selected from trehalose, mannitol, cellulose ethers, buffering agents, polyethylene glycols, surfactants, emulsifying agents and antioxidant compounds.

10. The ophthalmic composition as claimed in any one of claims 2, 4, 5, 6, 7, 8 or 9 in form of a liquid ophthalmic formulation.

11. The kit as claimed in any one of claims 3, 4, 5, 6, 7, 8 or 9, wherein at least one of said ophthalmic compositions a) and b) is in form of liquid ophthalmic formulation.

12. The ophthalmic composition as claimed in claim 10, wherein said liquid ophthalmic formulation comprises NGF at a concentration between 5 µg/ml and 300 µg/ml.

13. The kit as claimed in claim 11, wherein said ophthalmic composition a) is in form of liquid ophthalmic formulation and comprises NGF at a concentration between 5 µg/ml and 300 µg/ml.

14. The ophthalmic composition as claimed in claim 10 or 12, wherein said liquid ophthalmic formulation comprises sesamin at a concentration between 0.5 and 20 µg/ml.

15. The kit as claimed in claim 11 or 13, wherein said ophthalmic composition b) is in form of liquid ophthalmic formulation and comprises sesamin at a concentration between 0.5 and 20 µg/ml.

16. The ophthalmic composition as claimed in any one of claims 2, 4, 5, 6, 7, 8, or 9 in form of a powder formulation.

17. The kit as claimed in any one of claims 3, 4, 5, 6, 7, 8, 9, 11 or 15, wherein said ophthalmic composition a) is in form of a powder formulation, and said ophthalmic composition b) is in form of a liquid ophthalmic formulation.

18. Use of the ophthalmic composition according to any one of claims 2, 4, 5, 6, 7, 8, 9, 10, 12, 14, or 16 or the kit according to any one of claims 3, 4, 5, 6, 7, 8, 9, 11, 13, 15 or

17, in the manufacture of a medicament for the treatment of an ocular disorder known to be treatable by NGF, wherein the medicament is to be topically administered.

19. The use according to claim 1or claim 18, wherein said ocular disorder is selected from a corneal, conjunctival, scleral, retinal or optic nerve disorders.

20. The use as claimed in claim 19, wherein said ocular disorder is selected from toxic and phototoxic keratopathy, iatrogenic, immune and neurotrophic corneal epithelial defects and ulcers, neurotrophic keratopathy, neuropathic corneal pain, keratoconjunctivitis sicca, Sjögren's syndrome-associated dry eye, retinitis pigmentosa, retinal detachment, retinal degeneration subsequent to ischemia, phototoxic retinopathy, epiretinal membrane, macular hole, macular degeneration, optic neuropathies, glaucoma, scleritis and episcleritis.